ClinicalTrials.gg
RecruitingNCT07612046Updated Jul 9, 2026

A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

An observational study in Pancreatic Cancer and Pancreas Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
79
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center — 8 open to participants now, 20 under way, none of them phase 3. Pancreatic Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
8th of 12
79 · median 100
Started
2026
with 2 others
Observational
12 of 50
3 open now
Primary completion
2028-05
later than 17 of 19 live
Registered
48th of 50
by date

Among the 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2026, is one of 12 observational ones, reaches primary completion later than 17 of the 19 other live ones, and was the 48th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

8 of the 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Pancreatic Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

03

Conditions studied

  • Pancreatic Cancer
  • Pancreas Cancer

Keywords

  • Pancreatic Cancer
  • Pancreas Cancer
  • Memorial Sloan Kettering Cancer Center
  • 26-174
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
  • Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
  • Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
  • Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+

For this pilot MRP study, we will additionally apply the following Criteria:

  • Consents to follow-up contact
  • US residents
  • Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
  • No metallic artifacts covering the pancreas on prior MRCP
  • Scheduled for endoscopic ultrasound
  • No new for MRI (e.g. new MR unsafe device)
  • No history of claustrophobia or use of anxiolytic on prior MRI
  • No history of abdominal surgery that may affect interpretation of either EUS or MR
  • No medical conditions that confers increased and/or unacceptable risk for anesthesia

We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in \~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.

  • Documentation of Disease

    o No pathologic confirmation of disease is necessary

  • Definition of Disease N/A
  • Required Organ Function N/A

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
79 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants at high risk for pancreas ductal adenocarcinoma

    Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

    Diagnostic Test: MRI · Diagnostic Test: Endoscopic ultrasound

Interventions

  • Diagnostic testMRI

    Participants will undergo a single MRI of the abdomen without contrast

    Also known as: Magnetic Resonance CholangioPancreatography, MRP

  • Diagnostic testEndoscopic ultrasound

    EUS will be scheduled the same day or within 2 weeks prior to MRP

    Also known as: EUS

06

What researchers measure

Primary outcomes

  1. Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP

    Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.

    Time frame: Up to 3 years

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Consent Only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
  • Memorial Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
  • Memorial Sloan Kettering Bergen (Consent Only)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
  • Memorial Sloan Kettering Suffolk-Commack (Consent only)
    Commack, New York 11725, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
  • Memorial Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
    New York, New York 10065, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
  • Memorial Sloan Kettering Nassau (Consent Only)
    Uniondale, New York 11553, United States
    Recruiting
    • Richard Kinh Gian Do, MD, PhD · Contact212-639-8591
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2028, 24 months after the start.

Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 24 months is below that.

Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
May 20, 2026
Primary completionEst.
May 20, 2028
CompletionEst.
May 20, 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07612046
Responsible party
Sponsor
First posted
May 28, 2026
Start date
May 20, 2026
Primary completion
May 20, 2028 (estimated)
Completion
May 20, 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Richard Kinh Gian Do, MD, PhD
Contact
dok@mskcc.org
212-639-8591
Mengmeng Du, ScD
Contact
dumeng@mskcc.org
646-227-3495
Richard Kinh Gian Do, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion